INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
Stock Information for PhaseBio Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.